Biofrontera (BFRIW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BFRIW SEC filings page.
Biofrontera (BFRIW) reported $46.2M in revenue over the twelve months to Jun 30, 2026, up 17.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue expansion is narrowing operating losses, but persistent cash deficits keep growth dependent on external financing.
FY2025 revenue reached$41.7M while operating loss narrowed to$11.3M , showing that additional sales are reaching the operating line more efficiently. Yet cash conversion remains weak: operating cash flow of-$13.4M nearly matched free cash flow of-$13.4M , so the accounting improvement did not materially reduce the cash requirement.
Leverage improved, with debt-to-equity falling from 4.0x to 1.7x by FY2025, but that change does not reflect internally funded growth. The
Capital intensity is minimal: capital expenditure was only
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Biofrontera's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Biofrontera held $6.4M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $13.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Biofrontera scores 20/100 among other emerging companies.
Biofrontera had 12M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Biofrontera scores 19/100 among other emerging companies.
Biofrontera spent $3.7M on research and development in fiscal year 2025, which was 7.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Biofrontera scores 29/100 among other emerging companies.
Biofrontera reported revenue of $41.7M in fiscal year 2025, against $37.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Biofrontera scores 57/100 among other emerging companies.
Biofrontera's operations used $13.4M of cash in fiscal year 2025, against $10.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Biofrontera scores 70/100 among other emerging companies.
Biofrontera's cash, cash equivalents and investments came to $6.4M at the end of fiscal year 2025, against $18.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Biofrontera scores 36/100 among other emerging companies.
Biofrontera passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Biofrontera reported a net loss of $10.5M while operations used $13.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Biofrontera reported an operating loss of $11.3M against $452K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Biofrontera generated $12.0M in revenue in Q2 2026. This represents an increase of 32.9% from the same quarter a year earlier. Against the prior quarter it is up 19.0%.
Biofrontera's EBITDA was -$524K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 89.7% from the same quarter a year earlier. Against the prior quarter it is up 87.7%.
Biofrontera reported -$604K in net income in Q2 2026. This represents an increase of 88.7% from the same quarter a year earlier. Against the prior quarter it is up 87.3%.
Biofrontera earned -$0.05 per diluted share (EPS) in Q2 2026. This represents an increase of 91.2% from the same quarter a year earlier. Against the prior quarter it is up 87.8%.
Cash & Balance Sheet
Biofrontera recorded an outflow of $1.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 45.6% from the same quarter a year earlier. Against the prior quarter it is down 2110.7%.
Biofrontera held $4.7M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Biofrontera's operating margin was -4.4% in Q2 2026, reflecting core business profitability. This is up 51.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 38.5 percentage points.
Biofrontera's net profit margin was -5.0% in Q2 2026, showing the share of revenue converted to profit. This is up 53.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 42.1 percentage points.
Biofrontera's ROE was -10.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is up 68.2 percentage points.
Not reported for Q2 2026.
Capital Allocation
Biofrontera invested $448K in research and development in Q2 2026. This represents a decrease of 48.5% from the same quarter a year earlier. Against the prior quarter it is down 50.2%.
Biofrontera reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q2 2026.
BFRIW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0M+32.9% | $10.1M+17.4% | $17.1M+36.2% | $7.0M-22.5% | $9.0M+15.2% | $8.6M+8.5% | $12.6M+18.5% | $9.0M+1.3% |
| R&D Expenses | $448K-48.5% | $900K-25.4% | $788K+0.8% | $854K+27.7% | $870K+40.1% | $1.2M+7000.0% | $782K | $669K+1927.3% |
| SG&A Expenses | $9.6M-8.5% | $11.0M+27.1% | $8.5M+3.9% | $10.0M+19.3% | $10.5M+33.0% | $8.7M-6.5% | $8.2M-9.9% | $8.4M-2.3% |
| Operating Income | -$524K+89.7% | -$4.3M+5.0% | $4.6M+366.1% | -$6.3M-26.6% | -$5.1M-0.2% | -$4.5M+16.8% | -$1.7M+55.7% | -$5.0M-7.4% |
| EBITDA | -$524K+89.7% | -$4.3M+5.6% | N/A | N/A | -$5.1M-2.5% | -$4.5M+15.4% | -$1.7M+54.1% | -$4.8M-7.4% |
| Interest Expense | $126K+9.6% | $125K+4.2% | $106K | $111K | $115K-81.5% | $120K-91.6% | N/A | N/A |
| Income Tax | $23K+9.5% | N/A | -$1K+50.0% | $6K+100.0% | $21K+5.0% | -$1K-200.0% | -$2K+66.7% | $3K+200.0% |
| Net Income | -$604K+88.7% | -$4.8M-13.1% | $5.6M+504.0% | -$6.6M-17.3% | -$5.3M-1971.6% | -$4.2M+59.7% | -$1.4M-139.6% | -$5.7M+10.6% |
| EPS (Basic) | -$0.05+91.2% | -$0.41+12.8% | $0.63+270.6% | -$0.62+36.7% | -$0.57-1040.0% | -$0.47+83.7% | $0.17-96.3% | -$0.98+78.9% |
| EPS (Diluted) | -$0.05+91.2% | -$0.41+12.8% | $0.63+270.6% | -$0.62 | -$0.57 | -$0.47 | $0.17-96.3% | -$0.98 |
| Diluted Shares (Avg) | 13M+38.2% | 12M+31.7% | N/A | 11M | 9M | 9M | N/A | 6M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
BFRIW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $24.1M+19.5% | $24.8M+49.4% | $28.6M+29.2% | $15.4M-16.7% | $20.1M-6.6% | $16.6M-32.5% | $22.1M-20.9% | $18.5M-45.7% |
| Current Assets | $12.4M-33.9% | $13.2M-14.2% | $18.1M-12.6% | $14.4M-14.9% | $18.8M+7.7% | $15.3M-23.9% | $20.7M-10.3% | $16.9M-42.8% |
| Cash & Equivalents | $4.7M-35.6% | $6.3M+253.9% | $6.4M+8.2% | $3.4M+18.9% | $7.2M+65.3% | $1.8M-53.2% | $5.9M+339.7% | $2.9M-16.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $1.1M-72.8% | $1.2M-81.1% | $1.4M-78.5% | $4.3M-33.7% | $4.0M+2.1% | $6.5M-5.5% | $6.6M-39.1% | $6.5M-59.4% |
| Accounts Receivable | $5.5M+40.2% | $3.9M-3.8% | $7.3M+37.2% | $3.0M-38.6% | $4.0M+12.9% | $4.0M+14.5% | $5.3M+3.0% | $4.9M+28.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $18.1M-27.0% | $18.7M+16.1% | $18.1M+2.4% | $18.0M+38.6% | $24.8M+132.7% | $16.1M-39.0% | $17.7M-23.6% | $13.0M-60.7% |
| Current Liabilities | $10.5M-46.5% | $10.9M-0.3% | $11.9M-1.0% | $12.6M+13.8% | $19.7M+112.4% | $11.0M-21.9% | $12.0M-33.5% | $11.0M-62.1% |
| Non-Current Liabilities | $7.6M+47.7% | $7.8M+51.0% | $6.2M+9.6% | $5.4M+178.6% | $5.1M+267.2% | $5.2M-58.3% | $5.6M+11.8% | $2.0M-50.4% |
| Total Equity | $6.0M+227.6% | $6.1M+1194.2% | $10.5M+136.4% | -$2.6M-146.7% | -$4.7M-142.8% | $469K+108.7% | $4.4M-7.5% | $5.5M+432.8% |
| Retained Earnings | -$133.3M-5.0% | -$132.7M-9.1% | -$127.9M-9.0% | -$133.6M-15.1% | -$126.9M-15.0% | -$121.6M-10.5% | -$117.4M-17.8% | -$116.0M-12.4% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BFRIW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M+45.6% | -$70K+98.3% | -$2.4M-133.6% | -$3.8M-216.5% | -$3.0M+35.5% | -$4.1M-23.8% | -$1.0M+88.5% | -$1.2M+39.7% |
| Depreciation & Amortization | $0-100.0% | $55K+89.7% | N/A | N/A | $4K-96.7% | $29K-77.3% | $43K-81.3% | $129K+6.6% |
| Stock-Based Compensation | N/A | $342K+43.1% | N/A | N/A | N/A | $239K+4.8% | N/A | N/A |
| Capital Expenditures | $0-100.0% | $5K+66.7% | -$1K0.0% | -$1K | $1K-97.9% | $3K-94.7% | $1K-88.9% | $0 |
| Free Cash Flow | -$1.7M+45.6% | -$75K+98.2% | -$2.4M-133.5% | -$3.8M-216.6% | -$3.0M+36.1% | -$4.1M-21.8% | -$1.0M+88.5% | -$1.2M+39.7% |
| Investing Cash Flow | $0+100.0% | -$5K-66.7% | $3.0M+300200.0% | $1K | -$1K | -$3K | -$1K-101.4% | $0-100.0% |
| Financing Cash Flow | N/A | N/A | $2.4M-42.0% | $0+100.0% | N/A | N/A | $4.0M-39.7% | -$298K-150.4% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BFRIW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -4.4%+51.9pp | -42.8%+10.1pp | 26.6%+40.3pp | -89.8%-34.8pp | -56.3%+8.4pp | -52.9%+16.1pp | -13.6%+22.9pp | -55.0%-3.1pp |
| Net Margin | -5.0%+53.9pp | -47.1%+1.8pp | 33.0%+44.1pp | -95.2%-32.2pp | -59.0%-55.7pp | -48.9% | -11.1%-44.4pp | -62.9%+8.4pp |
| Return on Equity | -10.1% | -78.3%+817.9pp | 53.8%+85.3pp | N/A | N/A | -896.2% | -31.5%-105.1pp | -102.5%+508.5pp |
| Return on Assets | -2.5%+23.9pp | -19.2%+6.2pp | 19.8%+26.1pp | -43.1%-12.5pp | -26.4%-25.2pp | -25.3%+17.1pp | -6.3%-18.9pp | -30.6%-12.0pp |
| Current Ratio | 1.18+0.2x | 1.20-0.2x | 1.52-0.2x | 1.15-0.4x | 0.96-0.9x | 1.400.0x | 1.72+0.4x | 1.53+0.5x |
| Debt-to-Equity | 3.04 | 3.08-31.3x | 1.73-2.3x | N/A | N/A | 34.37 | 3.99-0.8x | 2.35-29.5x |
| Asset Turnover | 0.50+0.1x | 0.41-0.1x | 0.600.0x | 0.450.0x | 0.45+0.1x | 0.52+0.2x | 0.57+0.2x | 0.49+0.2x |
| FCF Margin | -13.8%+19.9pp | -0.7%+47.2pp | -13.9%-5.8pp | -54.7%-41.3pp | -33.7%+27.1pp | -48.0%-5.2pp | -8.1%+75.7pp | -13.4%+9.1pp |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Biofrontera BFRIW | FY2025 | $41.7M | -$10.5M | -25.3% | N/A | 39/100 |
| Biofrontera Inc BFRI | FY2025 | $41.7M | -$10.5M | -25.3% | $22.4M | 39/100 |
| Sunshine Biopharma Inc SBFM | FY2025 | $36.3M | -$6.0M | -16.5% | $4.3M | 59/100 |
| Sunshine Biopharma Inc SBFMW | FY2025 | $36.3M | -$6.0M | -16.5% | N/A | 59/100 |
| Incannex Healthcare Ltd IXHL | FY2025 | $86K | -$46.9M | N/A | $38.9M | — |
Where Biofrontera Ranks
Frequently Asked Questions
What is Biofrontera's annual revenue?
Biofrontera (BFRIW) reported $41.7M in total revenue for fiscal year 2025. This represents a 11.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biofrontera's revenue growing?
Biofrontera (BFRIW) revenue grew by 11.7% year-over-year, from $37.3M to $41.7M in fiscal year 2025.
Is Biofrontera profitable?
No, Biofrontera (BFRIW) reported a net income of -$10.5M in fiscal year 2025, with a net profit margin of -25.3%.
What is Biofrontera's EBITDA?
Biofrontera (BFRIW) had EBITDA of -$11.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biofrontera's operating margin?
Biofrontera (BFRIW) had an operating margin of -27.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biofrontera's net profit margin?
Biofrontera (BFRIW) had a net profit margin of -25.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biofrontera's return on equity (ROE)?
Biofrontera (BFRIW) has a return on equity of -100.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Biofrontera's free cash flow?
Biofrontera (BFRIW) recorded an outflow of $13.4M in free cash flow during fiscal year 2025. This represents a -30.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biofrontera's operating cash flow?
Biofrontera (BFRIW) recorded an outflow of $13.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Biofrontera's total assets?
Biofrontera (BFRIW) had $28.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biofrontera's capital expenditures?
Biofrontera (BFRIW) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biofrontera spend on research and development?
Biofrontera (BFRIW) invested $3.7M in research and development during fiscal year 2025.
What is Biofrontera's current ratio?
Biofrontera (BFRIW) had a current ratio of 1.52 as of fiscal year 2025, which is generally considered healthy.
What is Biofrontera's debt-to-equity ratio?
Biofrontera (BFRIW) had a debt-to-equity ratio of 1.73 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Biofrontera's return on assets (ROA)?
Biofrontera (BFRIW) had a return on assets of -36.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biofrontera's Piotroski F-Score?
Biofrontera (BFRIW) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biofrontera's earnings high quality?
Biofrontera (BFRIW) reported a net loss of $10.5M while operations used $13.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Biofrontera cover its interest payments?
Biofrontera (BFRIW) reported an operating loss of $11.3M against $452K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Biofrontera?
Biofrontera (BFRIW) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.